Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant/DoJ Probe Details Postmarket Reporting Meltdown With AAA Device

This article was originally published in The Gray Sheet

Executive Summary

A settlement between Guidant and the Department of Justice over deficient medical device reporting of deaths and serious injuries, combined with public awareness of the lapses, sets the stage for closer scrutiny of MDR practices across the industry

You may also be interested in...



AAA Endografts Show Early Promise In Lowering Mortality – Lancet Study

Longer-term follow-up is needed to confirm early clinical results showing a survival benefit for patients receiving endovascular aneurysm repair versus open surgery for abdominal aortic aneurysm treatment, according to an Aug. 25 Lancet study

AAA Endografts Show Early Promise In Lowering Mortality – Lancet Study

Longer-term follow-up is needed to confirm early clinical results showing a survival benefit for patients receiving endovascular aneurysm repair versus open surgery for abdominal aortic aneurysm treatment, according to an Aug. 25 Lancet study

Guidant, Boston Scientific Stocks Weather DES Issues

Guidant's July 1 confirmation that design changes to its Champion everolimus drug-eluting stent will only delay a launch by six to eight months appears to have partially allayed investor concerns after an initial stock sell-off in May

Related Content

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel